Source: Annual Congress 2008 - New insights into tuberculosis control
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
R. Goldman (Bethesda, United States of America). Facts and perspectives in the development of new anti-TB drugs. Annual Congress 2008 - New insights into tuberculosis control

Member's Comments

No comment yet.

Related content which might interest you: Facts and perspectives in the development of new diagnostics Source: Annual Congress 2008 - New insights into tuberculosis control Year: 2008 Clinical implications and opportunities for new drug therapies Source: Annual Congress 2008 - Deadly networks: disease-causing protein and DNA modifications Year: 2008 Rational use of new TB drugs in the EU Source: Annual Congress 2012 - New guidelines in respiratory infections Year: 2012 Perspectives on the new drugs pipeline Source: School Course 13 Year: 2013 Rational use of anti-tuberculosis drugs in the EU: better patient care and less drug resistance Source: Eur Respir J 2012; 39: 802-804 Year: 2012 Bronchiectasis: new therapies and perspectives Source: International Congress 2018 – Bronchiectasis: new insights in diagnosis and treatment Year: 2018 Prospects for new compounds tiosemikarbazonami class to create drugs with antituberculosis activity Source: International Congress 2014 – Tuberculosis: diagnosis Year: 2014 Tuberculosis elimination, patients' lives and rational use of new drugs: revisited Source: Eur Respir J 2016; 47: 664-667 Year: 2016 New anti-tuberculosis drugs and regimens: 2015 update Source: ERJ Open Res 2015; 1: 00010-2015 Year: 2015 Rational use of tuberculosis drugs to prevent the development of drug resistance Source: Annual Congress 2012 - MDR- and XDR-TB: epidemiological and public health overview Year: 2012 New methodologogic approaches to the management of antituberculous service Source: Eur Respir J 2003; 22: Suppl. 45, 381s Year: 2003 Resistance to second-line anti-tuberculosis drugs: new drug resistant TB treatment problem Source: Annual Congress 2007 - Drug-resistant and multidrug-resistant tuberculosis Year: 2007 Antimicrobial resistance and new therapeutic options Source: Virtual Congress 2021 – Community-acquired pneumonia: the new perspective in the post-COVID era Year: 2021 Classification of antituberculosis drugs: a new proposal based on the most recent evidence Source: Eur Respir J 2015; 46: 887-893 Year: 2015 Availability of anti-tuberculosis drugs in Europe Source: Eur Respir J 2012; 40: 500-503 Year: 2012